EUROBIO

ACCELERATION OF STRATEGIC DEPLOYMENT IN THE FIRST HALF OF 2023

ACCELERATION OF STRATEGIC DEPLOYMENT
IN THE FIRST HALF OF 2023

• Strong growth in half-year core business revenues, up 37%
• Successful deployment of the Group's strategy:
  • Share of proprietary products up, at 30% of revenues
  • Continued internationalization, with 35% of revenues now generated outside of France
• Acquisition of DID in Italy effective as of July 1^st, 2023
  
  

Paris, July 24, 2023 – 5:45 pm

Eurobio Scientific (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, today presents its consolidated half-year revenues for the period ending June 30, 2023.

Strong growth of core business at +37%

Eurobio Scientific recorded revenues of €59.1 million for its core business in the first half of 2023. Activities linked to the detection of COVID were not significant this semester and are now integrated to the core business (respiratory panels).
In H1 2022, the Group generated sales of €83.6 million. Excluding non-recurring sales from the COVID business (€40.6m), growth for H1 2023 therefore reached +37%.

On a comparable proforma basis, i.e. excluding perimeter effects linked to acquisitions and non-recurring items¹, growth of the core business remained dynamic, at +7%.

in €m		H1 2022					H1 2023	change. / core	at constant scope
		TOTAL	COVID		core
Revenues		83.6	40.6		43.0		59.1	+37%	+7%
unaudited

Successful deployment of the Group's strategy

The Group is successfully pursuing its strategy of targeted geographic and technological expansion, with the ambition of becoming a major international company in the specialty diagnostics market, providing its customers with a comprehensive molecular diagnostics offering, including its own solutions and those of its partners.

• Share of proprietary products reached 30% of revenues
  
  

The share of proprietary products increased to a high level, representing 30% of revenues (compared to 18% of core revenues in 2022), thanks in particular to the contribution of GenDx, consolidated in the Group's financial statements as of October 1^st, 2022.